Tirzepatide Stalled With PCOS: What Would New Labs Show?

The scale stopped moving a while ago. Your progress on tirzepatide stalled with PCOS in the background, the telehealth service that writes your prescription answered with a higher dose, and when that did not restart anything, it answered with another. Nobody told you why the first dose stopped working or what the next one was meant to fix. Then your doctor looked over your bloodwork and said it was fine, which sounded like good news and also seemed to close the conversation.

So the question is a fair one: if your labs are fine, why would you need more of them? This piece answers it through one person. Rachel is a composite, assembled from situations like yours; she is not a real patient, and her details are illustrative. What follows is her first three months as a GoodLife Health member: what a clinician would check, why each check is there, what the membership costs, and what none of it promises.

Higher doses, the same scale, and no explanation

Rachel was diagnosed with polycystic ovary syndrome long before she started tirzepatide through a telehealth service. The first stretch went the way she had hoped. The scale moved, her appetite quieted, and for a while it felt like the first treatment that had worked.

Then the numbers flattened. She logged the same weight week after week and sent a message through the app. The reply suggested moving up a dose. She did, the scale shifted a little, and then it flattened again. The next message brought the same answer. Over those months nobody asked about her cycles, her sleep, or whether anything else in her health had changed. PCOS was on her intake form, and as far as she could tell, nobody went back to it.

Her prescription is branded Zepbound, which she buys self-pay. Lilly's own price for Zepbound vials through LillyDirect, as published in September 2026, runs from $299 to $449 a month depending on dose. Each step up was also a decision about money, and she made it without knowing what the new dose was supposed to solve.

At her annual physical she mentioned the stall to her primary care doctor. He ran the usual bloodwork, and the portal note said everything was within normal limits. When she asked about her weight, he told her the labs looked fine and suggested she keep going.

Rachel came away with two conclusions, and she disliked both. Either the medication had stopped working for her, or she was doing something wrong and the labs had ruled out every other explanation. Neither had been tested. Nobody had looked for a reason, and "fine" had quietly become "there is nothing to find."

That is the situation this piece is about: a woman who has done what she was told, has paid for each new dose, and has been given a verdict where she needed an explanation.

What "your labs are fine" was actually measuring

When a doctor says your labs are fine, it usually means something specific and limited: the tests that were ordered came back inside their reference ranges. That is a useful finding. Nothing on that panel was flagged, and some problems you would want ruled out have been. What the finding cannot tell you is why a medication that was working has stopped.

Three questions sit underneath the word, and each is worth asking.

The first is which tests were on the panel. A routine annual panel is built to screen for common problems, and it may not have included fasting insulin, a full thyroid picture, a hormone panel, ApoB, Lipoprotein(a) or hs-CRP. A test that was never drawn cannot come back abnormal. If the answer to your stall lives in a marker nobody ordered, a clean panel will look reassuring and say nothing about it.

The second is what "in range" means. Reference ranges describe a broad population. Cardiometabolic Optimization: The Definitive Guide explains that GoodLife Health reads results against optimal ranges rather than population reference ranges. A value can sit inside the reference range and still deserve a conversation, especially when it is read alongside your other results and your history instead of on its own.

The third is when the blood was drawn. One panel is a snapshot; it cannot show direction, and direction is what you need when the question is why something changed. The guide says a quarterly re-audit is what turns a prescription from a guess into a feedback loop, and that this is what standard annual bloodwork structurally cannot do.

Then there is the system itself. The guide treats cardiometabolic health as one system and describes the chain this way: insulin resistance drives weight gain, visceral fat disrupts hormones, disrupted hormones stall metabolism, and stalled metabolism feeds vascular inflammation. It also notes that hormonal health is the part most often skipped, and a reason so many protocols stall. For a woman with PCOS, both the hormonal and the metabolic links in that chain are worth reading, so a stall has more than one possible explanation. A higher dose of tirzepatide is one lever. Insulin, thyroid function and hormones are others, and the only way to know which one matters for you is to look.

Why your prescriber kept raising the dose is something we cannot see, and their reasoning may have been sound. What we can describe is our own pricing: the GoodLife Health membership fee is the same whatever medication is indicated and whatever the dose, and GoodLife Health takes nothing on medication, so a clinician here has no financial reason to prefer a higher dose, a lower one, or one medication over another.

Rachel's first three months, and what each check is for

Before month one: the check, the intake and the review

Rachel started with the eligibility check, a short set of questions that comes before anything is charged. Then came the intake, where she described her PCOS diagnosis, her current prescription and dose, the history of each increase, and what her weight had done along the way. Then checkout: $598 at sign-up, covering the first two months of the $299 monthly membership. Then a clinician's review of everything she had submitted.

Not everyone is accepted. If the clinician cannot accept a patient into care, the $598 is refunded in full. Once a patient is accepted, the first two months are non-refundable, and medication billed by a pharmacy follows that pharmacy's own return and refund policy.

One note for readers whose prescription differs from Rachel's. Hers is branded. If yours is a compounded tirzepatide, GoodLife Health prescribes branded, FDA-approved medication only and never compounded GLP-1. The FDA has published its concerns about unapproved GLP-1 drugs used for weight loss, and a clinician's license carries the responsibility for what is prescribed. The clinician would talk through what this means for your prescription, plainly and without alarm.

Month one: the first panel, and why each part is on it

Rachel's first panel was drawn early in her membership. It is the first of four cardiometabolic lab panels included each year (the quarterly Biomarker Audit), and her clinician decided exactly what went on it. For a patient in her situation, it would look much like the panels described in the guide and in What a Direct Primary Care Visit Actually Looks Like, and each part answers a question her earlier care left open.

HbA1c and fasting insulin cover the blood sugar and insulin part of the system. They come first because the guide's chain starts with insulin resistance, and a blood sugar result read without insulin leaves that side of the question unasked.

A thyroid panel goes on because thyroid function belongs to the same system, and because thyroid medication can be prescribed within the membership where it is indicated. If her thyroid results changed the picture, the clinician could act on them in the same plan.

A hormone panel goes on, read with her PCOS diagnosis in view. Her hormonal results are read in the same sitting as her insulin results and her weight history, because the guide's whole argument is that these move together. If they pointed to treatment, hormone therapy can be prescribed where indicated.

Lipids, ApoB, Lipoprotein(a) and hs-CRP cover the cardiovascular and inflammation end of the chain. They may have nothing to do with her stall. They are on the panel because the membership is built for the long haul, and someone working on her weight with PCOS in the picture has good reason to know where her cardiovascular markers stand along the way.

A metabolic panel and a complete blood count give the baseline against which every later panel is read.

Every result went into Rachel's hands as numbers, with no one-word summary standing in for them. She and her clinician went through them on a video visit, marker by marker, with her tirzepatide history in front of them both.

Month two: a plan in place of a reflex

What happened next depended on what the panel showed, and the honest version of this scenario has more than one ending. If a result pointed somewhere, the clinician could address that finding and hold the dose while it was worked on. If nothing stood out on the markers that matter for her situation, that was useful too: the next conversation about the dose, the timing or the plan would rest on something firmer than a guess. Either way, Rachel would know why the plan was what it was.

Any medication was prescribed, when clinically indicated, to the pharmacy Rachel chose, at that pharmacy's own price. If she wanted to try her insurance for it, that was between her, her plan and her pharmacy. Prior authorization is the pharmacy's process; GoodLife Health does not run it and does not promise how it turns out.

Between visits she used asynchronous messaging with the care team. When she noticed something, or wanted to understand a result, she asked the people who had read her panel.

Month three: the second panel

Toward the end of her first quarter, Rachel drew her second panel. This is the step a single annual panel cannot take. Her clinician could now see which markers had moved, in which direction, and whether the plan from month two was doing what it was meant to do. If they moved as hoped, the plan continued. If they did not, that was information, and the plan changed with it.

Her weight might have started moving again by then, or it might not have. The membership does not promise either. What it gives her is a reason for every decision, written down and checked against her own numbers every quarter.

What it costs, and what it does not do

The membership is $299 a month, month to month. $598 is charged at sign-up and covers the first two months, and the membership comes to $3,588 a year. That fee covers clinicians licensed in all fifty states, four cardiometabolic lab panels a year, every result in your hands, asynchronous messaging with the care team, and video visits.

Medication is separate, and GoodLife Health sets nothing, sees nothing and takes nothing on it. Rachel's Zepbound stays at the self-pay price quoted above, billed by the pharmacy she uses. The membership fee is generally eligible for HSA or FSA pre-tax dollars.

The membership pairs with insurance for catastrophic coverage and does not replace it; it replaces the primary-care relationship. It does not guarantee weight loss, it does not promise that any medication will be covered, and it does not promise that a stall will end.

So, do you need more labs?

You may not need more labs for their own sake. You need the right ones, read together, against your history, by a clinician who then does something with them. If your doctor's panel included the markers above and you have the numbers, they are worth bringing; a clinician will usually still want a current panel of their own, because a stall is a question about what has changed.

"Fine" was a real answer to a narrow question. The question you have been carrying is a different one: why did a treatment that was working stop, and what should change? A higher dose is one possible answer to that. The labs are how a clinician finds out whether it is the right one.

GoodLife Health is a clinician-led practice built for that question: diagnosis first, then treatment, then the long haul. It sits between the $20,000-a-year concierge practice and the $99-a-month compounded app, and it says so. If the scenario above sounds like the care you expected when you started, the eligibility check is the place to begin.

Who this is not for

If you want the cheapest possible tirzepatide prescription and no labs, the $99-a-month compounded app is built for that, and this membership is not. GoodLife Health does not prescribe compounded GLP-1. If you are looking for a guaranteed dose increase, a promise of a specific medication, or a promise that insurance will cover it, the membership makes none of those promises. If you want something to replace your health insurance, it does not do that either. And if you already have a clinician who orders the full picture, reads it with your PCOS in mind, and explains every change, you may not need us. Keep that clinician.

Related Reading

• Cardiometabolic Optimization: The Definitive Guide
• What a Direct Primary Care Visit Actually Looks Like (2026)

References

1. Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
2. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss